Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE...

Area of Science:

• Cardiology
• Nephrology
• Endocrinology

Background:

• Cardiovascular outcome trials (CVOTs) are crucial for evaluating glucose-lowering agents in type 2 diabetes mellitus (T2DM).
• Sodium-glucose cotransporter-2 (SGLT2) inhibitors have emerged as a significant class due to demonstrated cardiovascular and kidney benefits.
• Recent clinical guidelines increasingly incorporate these findings.

Purpose of the Study:

• To review the mechanism of action and pleiotropic effects of SGLT2 inhibitors.
• To summarize the key findings and limitations of initial CVOTs for SGLT2 inhibitors.
• To discuss major kidney disease-focused outcome trials, including completed and ongoing studies.

Main Methods:

• Review of published cardiovascular outcome trials (CVOTs) and randomized controlled trials (RCTs).
• Analysis of the mechanism of action and pleiotropic effects of SGLT2 inhibitors.
• Discussion of specific trials: CREDENCE, and ongoing trials focusing on heart failure and kidney disease (e.g., EMPA-KIDNEY, Dapagliflozin trials).

Main Results:

• SGLT2 inhibitors demonstrate significant efficacy and safety in managing cardiovascular and kidney outcomes in T2DM patients.
• Initial CVOTs established the cardiovascular benefits, while subsequent trials focus on renal protection.
• Ongoing trials are further elucidating the role of SGLT2 inhibitors in diverse patient populations with kidney disease.

Conclusions:

• SGLT2 inhibitors represent a major advancement in T2DM management, offering substantial cardiovascular and renal benefits.
• The evidence supports their inclusion in clinical guidelines for T2DM patients, particularly those at high cardiovascular or kidney risk.
• Further research through ongoing trials will continue to refine the understanding and application of SGLT2 inhibitors in kidney disease management.